Bart Rikhof

645 citations

14 papers · 490 indexed · h-index 11

Impact in

Gastroenterology top 5%
- Gastrointestinal Tumor Research and Treatment
Rheumatology top 10%
- Soft tissue tumor case studies

Papers in

Gastroenterology 5
- Gastrointestinal Tumor Research and Treatment 5
Rheumatology 6
- Soft tissue tumor case studies 5

Co-authors: Winette T.A. van der Graaf Albert J.H. Suurmeijer Steven de Jong Coby Meijer J. van Doorn Henk Bilo A.H. Honkoop Wafik S. El‐Deiry
Journals: European Journal of Cancer (2 papers)Annals of Oncology (2 papers)British Journal of Cancer (1 paper)Cancer Biology & Therapy (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations: Netherlands Germany Canada

In The Last Decade

Bart Rikhof

13 papers receiving 475 citations

Peers

Countries citing papers authored by Bart Rikhof

Since Specialization

Citations

This map shows the geographic impact of Bart Rikhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Rikhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Rikhof more than expected).

Fields of papers citing papers by Bart Rikhof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Rikhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Rikhof. The network helps show where Bart Rikhof may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bart Rikhof, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bart Rikhof Line = papers co-authored together Bart Rikhof links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry European Journal of Cancer ·Martin W. Bloem, Karijn P.M. Suijkerbuijk, P. Polland, Franchette W.P.J. van den Berkmortel, Madison Korol, Willeke A.M. Blokx, Marye J. Boers‐Sonderen, Elly Meilany Br Sinaga, Jan Willem B. de Groot, Stefani Ferreira Rodrigues Santos, Geke A.P. Hospers, Ellen Kapiteijn, 竜也園部, Djura Piersma, Bart Rikhof, Nabil Majd None, César González Bueno, Gerard Vreugdenhil, Michel W.J.M. Wouters, Polina Artiushkina	2025	0
2	PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor–based First-line Therapy in Metastatic Renal Cell Carcinoma Patients European Urology Open Science ·N. V. Maslov, Patricia Zondervan, Rob Kessels, Johannes Berkhof, Maureen J.B. Aarts, Paul Hamberg, Marine Mosulishvili, AN. Kästner, Bart Rikhof, Britt B.M. Suelmann, Metin Tascilar, А. Ю. Борисов, Paul C.M.S. Verhagen, Hans M. Westgeest, محمد سلامة, Axel Bex, Adriaan D. Bins	2024	1
3	Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer European Journal of Cancer ·Jorianne Boers, Clasina M. Venema, Erik F. J. de Vries, Geke A.P. Hospers, Hendrikus H. Boersma, Bart Rikhof, Aditya R. Prabhukhot, Andor W.J.M. Glaudemans, Carolina P. Schröder	2020	13
4	Hypoglycemia in a Patient With a Big “Big”-IGF-II-Producing Tumor The Journal of Clinical Endocrinology & Metabolism ·X. R. Zhang, Martijn L. Bakker, Bart Rikhof, Frank F. A. IJpma, Robert J. van Ginkel, Philip M. Kluin, Jaap van Doorn, Robin P. F. Dullaart	2013	11
5	‘Big’-Insulin-Like Growth Factor–II Signaling Is an Autocrine Survival Pathway in Gastrointestinal Stromal Tumors American Journal Of Pathology ·Bart Rikhof, Winette T.A. van der Graaf, Albert J.H. Suurmeijer, Jaap van Doorn, Gert Jan Meersma, Patricia J.T.A. Groenen, Ed Schuuring, Coby Meijer, Steven de Jong	2012	16
6	The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. PubMed ·Melody Kwatemah Agyei-Fedieley, Winette T.A. van der Graaf, Bart Rikhof, Jorge Díaz García, Steven Teerenstra, Albert J.H. Suurmeijer, Uta Flucke, Jan Loeffen, Stefan Sleijfer, Eveline S.J.M. de Bont	2012	38
7	Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour Annals of Oncology ·Bart Rikhof, J. van Doorn, Albert J.H. Suurmeijer, Gladys I. Igbokwe, Patricia J.T.A. Groenen, Marian Verdijk, P.L. Jager, Steven de Jong, Jourik A. Gietema, Winette T.A. van der Graaf	2009	20
8	Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL British Journal of Cancer ·Bart Rikhof, Winette T.A. van der Graaf, Coby Meijer, Phuong Le, Gert Jan Meersma, Steven de Jong, Jonathan A. Fletcher, Albert J.H. Suurmeijer	2008	17
9	The insulin‐like growth factor system and sarcomas The Journal of Pathology ·Bart Rikhof, Steven de Jong, Albert J.H. Suurmeijer, Coby Meijer, Winette T.A. van der Graaf	2008	113
10	Age as a prognostic factor for outcome in patients (pts) with rhabdomyosarcoma (RMS) Journal of Clinical Oncology ·Melody Kwatemah Agyei-Fedieley, Winette T.A. van der Graaf, Bart Rikhof, Aune Kepilä, Jan Loeffen, Stefan Sleijfer, Eveline S. de Bont	2008	1
11	Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity Annals of Oncology ·Patrick J. Perik, Bart Rikhof, Floris A. de Jong, Jaap Verweij, Jourik A. Gietema, Winette T.A. van der Graaf	2007	45
12	Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases Endocrine Related Cancer ·Barton L. Johnke, Bart Rikhof, J. van Doorn, Henk Bilo, J. Gericke, A.H. Honkoop, Winette T.A. van der Graaf	2007	161
13	Non-islet cell tumour hypoglycaemia in a patient with a gastrointestinal stromal tumour Acta Oncologica ·Bart Rikhof, Gerrit van den Berg, Winette T.A. van der Graaf	2005	19
14	Caspase 10 Levels are Increased Following DNA Damage in a p53-Dependent Manner Cancer Biology & Therapy ·Bart Rikhof, Paul G. Corn, Wafik S. El‐Deiry	2003	35

About Bart Rikhof

Bart Rikhof is a scholar working on Gastroenterology, Rheumatology, Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Hematology, having authored 14 papers that have together received 490 indexed citations. Recurring topics across this work include Soft tissue tumor case studies (5 papers), Gastrointestinal Tumor Research and Treatment (5 papers), Growth Hormone and Insulin-like Growth Factors (4 papers), Sarcoma Diagnosis and Treatment (3 papers), Metabolism, Diabetes, and Cancer (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Cell death mechanisms and regulation (1 paper) and Medical Imaging Techniques and Applications (1 paper). The work is most often cited by research in Gastroenterology (80 citations), Rheumatology (131 citations), Pulmonary and Respiratory Medicine (227 citations), Endocrinology, Diabetes and Metabolism (107 citations) and Cancer Research (76 citations). Bart Rikhof has collaborated with scholars based in Netherlands, Germany and Canada. Frequent co-authors include Winette T.A. van der Graaf, Albert J.H. Suurmeijer, Steven de Jong, Coby Meijer, J. van Doorn, Henk Bilo, A.H. Honkoop, Wafik S. El‐Deiry, Paul G. Corn and Jourik A. Gietema. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, British Journal of Cancer, Cancer Biology & Therapy and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact